Aberdeen based medical device company SIRAKOSS Ltd has received two patents for its bone graft technologies from the United States Patent and Trademark Office (USPTO).
SIRAKOSS is developing innovative bone grafting solutions for the $3 billion global orthopaedic market and its patent portfolio encompasses advanced synthetic bone graft technologies which form the company’s product pipeline designed to address the significant clinical need for a fully-synthetic, standalone bone void filler.
Subscribe to our daily newsletter
Why? Free to subscribe, no paywall, daily business news digest.
The two new granted patents are important additions to SIRAKOSS’ intellectual property estate and significantly enhance the company’s technology and product pipeline. Patent US 9,492,591 describes novel formulations of putty products, where the SIRAKOSS core technology may be combined with modified resorbable polymer carriers to produce a bone graft with improved handling characteristics and enhanced efficacy. The second patent (US 9,492,585) describes a range of bone graft technologies with specific microstructural properties that expands the potential products that SIRAKOSS can develop. These two new patents add to SIRAKOSS’ robust existing granted patents in Europe, Japan, Australia and China, and to the company’s core IP estate in the USA, Japan and Australia.
These patent grants occur as SIRAKOSS is advancing the development of its lead technology in Europe toward market.
The company’s proprietary technology is entirely synthetic, containing no human tissue and can be manufactured in consistent, high quality batches. Surgeon feedback on pre-clinical performance data and handling properties of the SIRAKOSS bone graft substitutes, when compared to currently available products, has been very encouraging. The alternative approach against which all other options are measured is autograft – the ‘gold standard’ – where healthy bone is harvested from the patient’s hip and replanted at the defect site. The amount of bone that is available for grafting is limited, particularly in children, and requires two invasive operative procedures, increasing the risk for the patient and the cost for the hospital. Other alternatives have seen products derived from cadaver bone, but these can be inconsistent in their performance.
Brian Butchart, CEO of SIRAKOSS, said “The granting of these two patents endorses the breadth of our technology and provides SIRAKOSS further protection for its unique product offerings in the largest single market for bone graft substitutes.”
Investor director, Sinclair Dunlop, Managing Partner at Epidarex Capital, said “this welcome expansion of SIRAKOSS’ global IP estate furthers the competitiveness of the company’s core technology and its potential for meeting a large market, driven by patient needs”
Synthetic bone grafts are used in trauma, spinal and dental surgery to fuse bones together to correct congenital or degenerative conditions (such as curvature of the spine) or following a traumatic injury where the bone fails to heal.